Document is current
Any future updates will be listed below
-
Authors
Boixareu, Cristina https://orcid.org/0000-0002-7630-3556
Taha, Tarek https://orcid.org/0000-0001-7936-5245
Venkadakrishnan, Varadha Balaji https://orcid.org/0000-0001-7071-4584
de Bono, Johann https://orcid.org/0000-0002-2034-595X
Beltran, Himisha https://orcid.org/0000-0003-3259-2226
- License Information
-
More Information
Article History
Accepted: 5 March 2025
First Online: 1 April 2025
Competing interests
: H.B. has served as consultant/advisory board member for Janssen, AstraZeneca, Merck, Pfizer, Amgen, Bayer, Daiichi Sankyo and Novartis, and has received research funding (to their institution) from Janssen, Bristol Myers Squibb, Circle Pharma, Daiichi Sankyo and Novartis. J.d.B. has served as an adviser for Daiichi Sankyo, AstraZeneca, MSD, Pfizer, Amgen, Bayer, Merck Serono, Janssen, GSK, Macrogenics, Actinium Pharma, Astellas, Amunix and Sanofi-Aventis. The other authors declare no competing interests.
